Chemomab Therapeutics Ltd. has announced the presentation of positive Phase 2 clinical data for their investigational drug, nebokitug, at BSG Live'25, the annual scientific meeting of the British Society for Gastroenterology in Glasgow, UK. The data, from the SPRING trial, indicates that nebokitug is well-tolerated and associated with significant improvements in fibrotic and inflammatory biomarkers in patients with primary sclerosing cholangitis $(PSC.AU)$. These improvements suggest a potential slowing of disease progression. The findings support the advancement of nebokitug to a Phase 3 trial, positioning it as a potential first-in-class treatment for PSC. The results were presented by Professor Douglas Thorburn, the Principal Investigator of the SPRING trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.